Presentation

Company Profile
ProstaLund is a Swedish medtech company, that develops and commercialises innovative products and treatments in the space of urology. ProstaLund has patented CoreTherm®, an individualized thermotherapy treatment for benign prostatic hyperplasia (BPH). CoreTherm works by heating the prostate tissue so that parts of it become necrotic. CoreTherm® is used today in hospitals and outpatient clinics in Sweden and around the world. ProstaLund AB’s subsidiary Nordisk Medicin & Teknik AB provides products to simplify work within healthcare.

Recent highlights
In Q2 2021. ProstaLund reported net sales of SEK 3,179 (1,551) thousand, demonstrating an increase of 105% year-to-year. In January, the company announced that in a Swedish comparative registry study, patients treated with CoreTherm® demonstrated half the risk of getting prostate cancer than patients who have had surgery with TURP. In March, the company announced that it was signed an agreement with region Västra Götaland for the supply of CoreTherm disposables. On the same Month, the company announced that another university hospital in Denmark started using CoreTherm. In June, the company announced that CoreTherm® has passed the efficacy and safety evaluation by "Nye Metoder" in Norway. In July, the company announced that, in collaboration with Oruba Medikal Teknoloji Ltd., it launched a new product, Oruflow, which is a urine flow meter.

Outlook
For 2021, ProstaLund’s goal is to reach sales of 1,500 CoreTherm. The company’s focus continues to be the Nordic market, where they have established a strong base in Sweden and growing in Denmark and Norway.